1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,340 | 10,420 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.04. | Devyser Q1 2025 slides reveal mixed results with 8% growth, EBIT challenges | 1 | Investing.com | ||
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 282 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 106 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 187 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 261 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 148 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 677 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 128 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen | |
| 23.07.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2024 | 168 | GlobeNewswire (Europe) | "Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large tenders during the... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 76,53 | -0,20 % | Medtronic plc-Aktie mit leichten Kursgewinnen (75,8105 €) | Im Wertpapierhandel liegt die Aktie von Medtronic plc aktuell im Plus. Das Wertpapier notiert zur Stunde bei 86,75 US-Dollar. Die Aktie von Medtronic plc verzeichnet gegenwärtig ein Kursplus von 1,34... ► Artikel lesen | |
| HCA HEALTHCARE | 336,70 | -0,15 % | Is HCA Healthcare Stock Outperforming the Nasdaq? | ||
| LANTHEUS | 70,76 | -1,17 % | Lantheus Holdings, Inc.: Lantheus Announces Sale of SPECT Business to SHINE Technologies | Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®... ► Artikel lesen | |
| AMEDISYS | 82,50 | 0,00 % | Amedisys Q1 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Amedisys (AMED) announced earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
| ENVISTA | 16,600 | +0,61 % | Hitachi Digital Services Announces Five-Year Strategic IT Partnership with Envista | DALLAS, May 15, 2025 /PRNewswire/ -- Hitachi Digital Services, the digital consultancy and technology services subsidiary of Hitachi, Ltd. (TSE: 6501), today... ► Artikel lesen | |
| CAREDX | 16,670 | -2,63 % | CareDx kündigt neues Aktienrückkaufprogramm über 50 Millionen US-Dollar an | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Third Quarter 2025 Results | Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow
HENDERSON... ► Artikel lesen | |
| GT BIOPHARMA | 2,750 | +1,48 % | GT Biopharma, Inc.: GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals | Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results... ► Artikel lesen | |
| CARMAT | 0,850 | +0,24 % | CARMAT Announces the First Commercial Implants of Its Aeson Artificial Heart Outside the European Union | Two implants have recently been performed in Israel
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide... ► Artikel lesen | |
| CHEMOMETEC | 70,55 | 0,00 % | Chemometec A/S: Continued growth in revenue and operating profit | Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | -90,48 % | Polarean: FDA expands XENOVIEW indication to include children from six years of age | ||
| ARRAIL GROUP | 0,195 | -1,52 % | ARRAIL GROUP (06639): NEXT DAY DISCLOSURE RETURNS | ||
| PROMIMIC | 1,690 | -0,30 % | Curiteva & Promimic - Bonded by Innovation | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,650 | +0,26 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS | 44,290 | +0,11 % | Fresenius SE: Die Rallye scheint noch nicht vorbei zu sein | Die Fresenius-Aktie entwickelt sich schon länger sehr positiv und zeigt seit Jahresbeginn ein überzeugendes Bild Den vollständigen Artikel lesen ... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,060 (+0,59 %) liegt der Kurs bei 10,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.